

# ~SAVE THE DATE~

**September**  
21-24, 2010

Tallinn, Estonia

## The Second Global Forum on TB Vaccines: A Framework for Introducing Improved TB Vaccines to the World Community

**Sponsors: Aeras Global TB Vaccine Foundation  
Stop TB Partnership Working Group on New TB Vaccines  
The Tuberculosis Vaccine Initiative**

### Background and Objectives:

The first “Global Forum” held on June 7-8, 2001 in Geneva, Switzerland, concluded that the “driving force” for identifying improved vaccines for tuberculosis over the next ten years would be moving investigational TB vaccines into human clinical trials. The major objectives of the “Second Global Forum” to be held September 21-24, 2010 in Tallinn, Estonia are to review the progress in the TB vaccine field over the last decade and to re-frame the global agenda and timelines for introducing improved TB vaccines into practice. Using five major topics established at the first Forum, current challenges and proposed solutions will be discussed and recommendations to keep the field moving forward will be identified. This will be done through expert presentations on critical topics over two days and workshops to identify new recommendations on day three. The conference will incorporate the current goals of the Stop TB Partnership and other national and international TB initiatives, emphasizing coordination with TB diagnostics development.

### Advisory Panel

#### Chair:

*Michael Brennan*, Aeras Global TB Vaccine Foundation

#### Members:

*Ulrich Fruth*, World Health Organization

*Jelle Thole*, Tuberculosis Vaccine Initiative

*Jan Gheuens*, The Bill & Melinda Gates Foundation

*Stefan H.E. Kaufmann*, Max Planck Institute for Infection Biology

*Greg Hussey*, Institute of Infectious Disease & Molecular Medicine

*Christine Sizemore*, National Institutes of Health

*Rick O'Brien*, Foundation for Innovative New Diagnostics



Tallinn, Estonia

### Conference Topics

- **Basic Research**—new findings in molecular, immunological, and pathogenesis and epidemiologic research, vaccine delivery and adjuvants.
- **Applied Research**—vaccine products; assay development; biomarkers; and preclinical studies.
- **Clinical Studies on TB Vaccines**—vaccines in clinical studies; lessons learned from trials; immunization strategies; phase II and III studies; next generation vaccines.
- **Manufacturing, Regulation and Vaccine Access**—pilot facilities; industrial development of TB vaccines; role of developing countries; IP issues and technology transfer; global regulation pathways; GMP assays.
- **Partnerships, Communication & Coordination**—role of major institutions and international organizations in TB vaccine development; coordinating new vaccine and new diagnostics studies; working in developing countries.

[More information to follow](#)